NIRADS 在 F-18 FDG PET/CT 头颈部恶性肿瘤治疗后评估中的诊断性能——系统综述与 Meta 分析
该系统综述与 Meta 分析纳入 8 项回顾性研究(7 个数据集,超过 1200 例患者、超过 1300 次 F-18 FDG PET/CT 扫描),评估 NIRADS 分类在头颈部鳞状细胞癌治疗后检出复发或治疗失败的诊断性能。合并原发、淋巴结或远处部位后,NIRADS ≥3 较 NIRADS ≤2 检出复发的汇总敏感度为 0.68(95%CI 0.63-0.73)、特异度为 0.90(95%CI 0.88-0.92),AUC 为 0.859(SE 0.018),证据确定性低。
要点
- NIRADS ≥3 较 NIRADS ≤2 检出复发的汇总敏感度 0.68(95%CI 0.63-0.73)、特异度 0.90(95%CI 0.88-0.92)。
- 汇总诊断比值比 DOR 为 14.13(95%CI 9.78-20.42),SROC 曲线 AUC 为 0.859(SE 0.018)。
- 作者认为 NIRADS 分类(尤其 NIRADS ≥3 与 NIRADS ≤2)应常规报告于 HNSCC 治疗后 F-18 FDG PET/CT 报告中,证据确定性低。
核心结论
- 在治疗后头颈部鳞状细胞癌患者的 F-18 FDG PET/CT 中,NIRADS ≥3 较 NIRADS ≤2 在合并原发、淋巴结或远处部位检出治疗失败或复发的诊断性能可接受,但证据确定性低。
研究设计与样本
- 系统检索 PubMed、Scopus、Cochrane Library 和 Google Scholar 至 2024 年 11 月 7 日,纳入按 NIRADS 标准报告 F-18 FDG PET/CT 治疗后复发率的研究。
- 共纳入 8 项研究(7 个数据集),超过 1200 例患者、超过 1300 次 F-18 FDG PET/CT 扫描。
- 采用 QUADAS-2 工具定性评估偏倚风险,将 NI-RADS ≤2 归为复发低风险、NI-RADS ≥3 归为复发高风险。
- 通过诊断准确性标准指标的加权合并、诊断比值比(DOR)及 SROC 曲线分析评估 NI-RADS 的诊断性能。
主要发现
- 所有纳入研究均为回顾性,存在偏倚风险、发表偏倚和数据异质性。
- 治疗结束至 F-18 FDG PET/CT 评估的时间为 8-17 周。
- 合并原发、淋巴结或远处部位后,NIRADS ≥3 较 NIRADS ≤2 检出复发的汇总敏感度为 0.68(95%CI 0.63-0.73),特异度为 0.90(95%CI 0.88-0.92)。
- 汇总阳性似然比为 6.01(95%CI 2.9-12.6),阴性似然比为 0.47(95%CI 0.31-0.71)。
- DOR 为 14.13(95%CI 9.78-20.42),SROC 分析 AUC 为 0.859(SE 0.018)。
关键数值与推荐
- 将 NI-RADS ≤2 定义为复发低风险,NI-RADS ≥3 定义为复发高风险。
- NIRADS ≥3 较 NIRADS ≤2 检出复发的汇总敏感度 0.68(95%CI 0.63-0.73)、特异度 0.90(95%CI 0.88-0.92)。
- 汇总阳性似然比 6.01(95%CI 2.9-12.6)、阴性似然比 0.47(95%CI 0.31-0.71)、DOR 14.13(95%CI 9.78-20.42)。
- SROC 分析 AUC 为 0.859(SE 0.018)。
临床怎么用
- 作者认为 NIRADS 分类,尤其是 NIRADS ≥3 与 NIRADS ≤2 分类,应常规报告于头颈部鳞状细胞癌患者治疗后的 F-18 FDG PET/CT 扫描中。
局限性
- 所有纳入研究均为回顾性。
- 存在偏倚风险、发表偏倚和数据异质性。
- 证据确定性低。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This review aimed to evaluate the diagnostic performance of Neck Imaging Reporting and Data System (NIRADS) categories using 2-deoxy 2-(Fluorine-18) fluoro D-glucose positron emission tomography integrated with computed tomography (F-18 FDG PET/CT) to diagnose recurrence or treatment failure in the post-treatment assessment of head and neck squamous cell carcinoma (HNSCC). METHODS: A systematic search of the indexed medical literature was conducted till 7 November 2024 using PubMed, Scopus, Cochrane Library and Google Scholar to include studies reporting post-treatment recurrence rates on F-18-FDG PET/CT as per the NIRADS criteria. Studies were qualitatively assessed for risk of bias using the QUADAS-2 tool. We categorized patients with 'NI-RADS≤2' as low risk of recurrence and 'NI-RADS ≥3' as high risk of recurrence. Diagnostic performance of NI-RADS was evaluated through weighted-pooling of standard metrics of diagnostic accuracy, diagnostic Odd's ratio (DOR) and summary receiver operator characteristic (SROC) curve analysis. RESULTS: Out of 1632 records identified, 8 studies with 7 datasets were included, with over 1200 patients and over 1300 F-18 FDG PET/CT scans. All studies were retrospective, with presence of a risk for bias, publication bias and data heterogeneity. The time between treatment and F-18 FDG PET/CT assessment was 8-17 weeks. For combined sites (primary, nodal or distant sites), the ability of 'NIRADS ≥3' over 'NIRADS ≤2' to detect a recurrence was acceptable with a pooled sensitivity, specificity, positive and negative likelihood ratios of 0.68 (95% Confidence Interval, CI 0.63-0.73), 0.90 (95% CI, 0.88-0.92), 6.01 (95% CI, 2.9- 12.6) and 0.47 (95% CI, 0.31- 0.71) respectively, with a DOR of 14.13 (95% CI, 9.78-20.42) and an area under the curve, AUC of 0.859 (Standard Error, SE -0.018) on SROC analysis CONCLUSION: In F-18 FDG PET/CT done on post-treatment HNSCC patients, the diagnostic performance of NIRADS ≥3 categories over NIRADS ≤ 2 categories in detecting treatment failure or recurrence at combined primary, nodal or distant sites was acceptable, with a low certainty of evidence. The NIRADS categories, especially NIRADS ≥3 and NIRADS ≤2 categories should be routinely reported in post-treatment F-18 FDG PET/CT scans in HNSCC patients. (No funding received; PROSPERO No. CRD42022376017).
引用
- Datta D, Selvakumar B, Goel AD, et al. Diagnostic performance of NIRADS on F-18 FDG PET/CT in the post-treatment assessment of head and neck malignancies - a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2025. PMID: 40137977. doi:10.1007/s00259-025-07230-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。